drugset / Trial / NCT06645197
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
Phase 0
Not yet recruiting
7 enrolled
Peking University Third Hospital
SineuGene Therapeutics Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2024-10-16
- Primary completion
- 2025-04-15
- Completion
- 2029-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNUG01 | Gene therapy (AAV / viral vector) | — | Intrathecal |